Gilles A Salles

Gilles A Salles

UNVERIFIED PROFILE

Are you Gilles A Salles?   Register this Author

Register author
Gilles A Salles

Gilles A Salles

Publications by authors named "Gilles A Salles"

Are you Gilles A Salles?   Register this Author

16Publications

935Reads

31Profile Views

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

N Engl J Med 2018 09;379(10):934-947

From Université Lille, Centre Hospitalier Universitaire (CHU), Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille (F.M.), CHU Régional de Nancy, Service d'Hématologie, Vandoeuvre lès Nancy (P.F.), Institut Paoli-Calmettes (R.B.) and Department of Pathology, Institut Paoli-Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM, Centre National de la Recherche Scientifique, Aix-Marseille Université (L.X.), Marseille, Centre Henri Becquerel, Unité 1245 and Département d'Hématologie, Université de Rouen, Rouen (H.T.), Institut d'Hématologie de Basse Normandie, Caen (C.F.), CHU Le Bocage Service d'Hématologie Clinique, Dijon (R.-O.C.), Hôpital Henri Mondor Unité Hémopathies Lymphoïdes, Créteil (C.H.), Centre Hospitalier Départemental Vendée Service d'Onco-Hématologie, La Roche sur Yon (H.M.), Institut Universitaire du Cancer de Toulouse Oncopole Service d'Hématologie, Toulouse (L.Y.), CHU Bordeaux, Service d'Hématologie, Bordeaux (K.B.), Hôpital Saint Louis Service d'Onco-Hématologie, Paris (P.B.), Gustave Roussy Cancer, Villejuif (V.R.), Centre Hospitalier Annecy Genevois Service, Annecy (N.D.), CHU de Nantes-Hôtel Dieu Service d'Hématologie Clinique, Centre de Recherche en Cancerologie et Immunologie, INSERM, Centre National de la Recherche Scientifique, Université de Nantes, Nantes (S.L.G.), Centre Hospitalier Métropole Savoie Service Hématologie, Chambery (G.M.P.), Department of Hematology, CHU Montpellier, University of Montpellier, Montpellier (G.C.), and Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, University of Lyon, Pierre-Benite (G.A.S.) - all in France; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (N.H.F.); the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (M.L.P.); the Department of Medicine, Division of Medical Oncology, University of Washington, Seattle (E.N.L.); Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.W.F.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (N.L.B.); the Department of Hematology, Hospital Universitario de Salamanca and Instituto de Investigación Biomédica de Salamanca, Centro de Investigación Biomédica en Red de Cáncer, Salamanca (A.M.G.-S.), and the Department of Hematology, Hospital Clinic de Barcelona, Barcelona (A.L.-G.) - both in Spain; CHU de Québec, Hôpital de l'Enfant-Jésus, Quebec (J.-F.L.), and British Columbia Cancer Centre for Lymphoid Cancer, University of British Columbia, Vancouver (L.H.S.) - both in Canada; the Department of Hematology and Oncology, Tokai University Hospital, Kanagawa, Japan (K.A.); Instituto Português de Oncologia Lisboa Francisco Gentil Departamento de Hematologia, Lisbon (M.G.S.); the Department of Hematology, CHU Université Catholique de Louvain Namur, Yvoir (M.A.), and the Department of Hematology, Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp (P.Z.) - both in Belgium; the Department of Hematology, National Cancer Center Hospital, Tokyo, Japan (K.T.); and Celgene, Summit, NJ (D.L., J.W.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805104
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805104DOI Listing
September 2018

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

J Clin Oncol 2018 06 19;36(16):1603-1610. Epub 2018 Apr 19.

Matthew J. Maurer, Thomas M. Habermann, Carrie A. Thompson, Cristine Allmer, Patrick B. Johnston, Ivana N. Micallef, David J. Inwards, William R. Macon, Andrew L. Feldman, Susan L. Slager, Stephen M. Ansell, James R. Cerhan, Thomas E. Witzig, and Grzegorz S. Nowakowski, Mayo Clinic, Rochester, MN; Hervé Ghesquières and Gilles A. Salles, Université Claude Bernard, Lyon; Jean-Philippe Jais, Richard Delarue, Thierry J. Molina, Hopital Necker, Paris; Corinne Haioun, Groupe Hospitalier Mondor, Créteil; Frederic Peyrade, Centre Antoine Lacassagne, Nice; Olivier Fitoussi, Polyclinique Bordeaux Nord-Aquitaine, Bordeaux; Hervé Tilly, Centre de lutte Contre le Cancer Henri Becquerel, Rouen, France; Brian K. Link, Umar Farooq, Sergei Syrbu, and George J. Weiner, University of Iowa, Iowa City, IA; and Nicolas Ketterer, Clinique Bois-Cerf, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.5198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978469PMC
June 2018

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.

Blood 2017 06 21;129(22):3037-3039. Epub 2017 Mar 21.

Department of Medicine, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-12-757740DOI Listing
June 2017

Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.

Cancer J 2016 Jan-Feb;22(1):12-6

From the *Faculté de Médecine Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon-1; †Laboratoire d'Hématologie Biologique, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud; ‡INSERM U1052, Equipe "Clinical and Experimental Models of Lymphomagenesis," Cancer Research Center of Lyon; and §Unité de Pharmacie Clinique Oncologique, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon; ‖Université Claude Bernard Lyon-1, EMR 3738, Pierre-Bénite; and ¶Service d'Hématologie Clinique, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000167DOI Listing
November 2016

New Agents to Treat Chronic Lymphocytic Leukemia.

N Engl J Med 2016 06;374(22):2185-6

Ernest and Helen Scott Haematological Research Institute, Leicester, United Kingdom

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1602674DOI Listing
June 2016

Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.

J Clin Oncol 2015 Nov 12;33(33):3930-7. Epub 2015 Oct 12.

Hervé Ghesquieres, Universite Claude Bernard Lyon 1, Centre Leon Berard; Amelie S. Veron and David G. Cox, L'Institut National de la Santé et de la Recherche Médicale (INSERM) U1052, Cancer Research Center of Lyon, Centre Leon Berard, Lyon; Hervé Ghesquieres and Gilles A. Salles, Faculté de Médecine Lyon-Sud; Gilles A. Salles, Universite Claude Bernard Lyon 1, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite; Fabrice Jardin, Sylvain Mareschal, and Herve Tilly, INSERM U918, Centre Henri Becquerel, Rouen; Thierry Fest, INSERM U917, Université de Rennes 1, Hopital Pontchaillou; Thierry Lamy, Université de Rennes 1, Hopital Pontchaillou, Rennes; Marie C. Bene, Centre Hospitalier Universitaire Nantes, Nantes; Corinne Haioun, Hospital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP) and University Paris Est, Créteil; Thierry Jo Molina, Universite Paris Descartes, AP-HP, Hôpital Necker, Paris; Noel Milpied, University Hospital and University of Bordeaux, Bordeaux, France; Hervé Ghesquieres, Susan L. Slager, Matthew J. Maurer, Thomas M. Habermann, Anne J. Novak, Stephen M. Ansell, Thomas E. Witzig, Andrew L. Feldman, Ahmet Dogan, Julie M. Cunningham, Curtis L. Olswold, and James R. Cerhan, Mayo Clinic, Rochester, MN; Yan W. Asmann, Mayo Clinic, Jacksonville, FL; and George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.2573DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879713PMC
November 2015

Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma.

Haematologica 2015 May 30;100(5):e204-6. Epub 2015 Jan 30.

Anticancer Antibody Team, INSERM U1052, CNRS UMR 5286, Cancer Research Center of Lyon, France Hospices Civils de Lyon, France ProfileXpert, Lyon, France Laboratory of Hematology, Hospices Civils de Lyon, Pierre-Bénite, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2014.120113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420233PMC
May 2015

Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.

J Clin Oncol 2009 Nov 28;27(33):5573-9. Epub 2009 Sep 28.

Assistance Publique-Hôpitaux de Paris, Groupe Henri Mondor-Albert Chenevier, L'Institut National de la Santé et de la Recherche Médicale, Unité 955, Institut Mondor de Recherche Biomédicale; Université Paris 12, Faculté de médecine, Créteil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.22.7058DOI Listing
November 2009

Clinical features, prognosis and treatment of follicular lymphoma.

Authors:
Gilles A Salles

Hematology Am Soc Hematol Educ Program 2007 :216-25

Centre Hospitalier Lyon-Sud, 165, Ch du Grand Revoyet, 69495 Pierre-Benite, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2007.1.216DOI Listing
July 2009